Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Carbonate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    124 result(s) found for: Carbonate. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2004-001608-11 Sponsor Protocol Number: SPD405-310 Start Date*: 2004-11-18
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End S...
    Medical condition: Hyperphosphataemia in Patients Receiving Haemodialysis for End Stage Renal Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000308-82 Sponsor Protocol Number: oxalate01 Start Date*: 2017-02-08
    Sponsor Name:Universitair Ziekenhuis Brussel
    Full Title: Lanthanum Carbonate (Fosrenol®) to reduce oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis: a short-term, prospective, open-label, efficacy and safety clinical trial
    Medical condition: Urolithiasis and secondary hyperoxaluria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000171-17 Sponsor Protocol Number: SPD405-207 Start Date*: 2012-10-02
    Sponsor Name:Shire Pharmaceutical Development Ltd.
    Full Title: A Three Part Open-Label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, compare the Efficacy, Safety and Tolerability of 8 weeks treatment with Lanthanum Carbonate and Calcium Carbonat...
    Medical condition: Treatment of Hyperphosphataemia.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) Outside EU/EEA CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-003158-15 Sponsor Protocol Number: GA1406 Start Date*: 2014-10-10
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A randomised, assessor blind, placebo controlled exploratory study in healthy volunteers, to characterise the acid neutralisation activity of sodium alginate oral suspension in the fasted state, us...
    Medical condition: To pilot the use of a custom designed pH catheter for the measurement of intragastric pH to characterise the antacid action of Gaviscon Double Action versus placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000825-11 Sponsor Protocol Number: P160914J Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Lithium effect in patients with Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 haploinsuffisance): pilot study.
    Medical condition: Autistic Spectrum Disorder and Phelan-McDermid Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000704-25 Sponsor Protocol Number: PASP01 Start Date*: 2017-02-28
    Sponsor Name:Queen Mary University of London
    Full Title: Prevention of Aortic Stenosis Pilot Trial
    Medical condition: Aortic Stenosis. It is caused by the build-up of calcium phosphate crystals on the aortic valve (aortic sclerosis). Progressive valve narrowing (stenosis) leads to symptoms (chest pain, syncope or ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004340-35 Sponsor Protocol Number: CAMG-14-I Start Date*: 2015-03-03
    Sponsor Name:Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Full Title: Randomized controlled trial of two different combinations of Calcium-containing Phosphate binders (Ca-PiB) plus non-Calcium-non-Aluminum containing Phosphate binders (no-Ca-Al-PiB): a pharma-econom...
    Medical condition: Hyperphosphatemia associated with Chronic Kidney Disease (CKD) in patients undergoing hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002280-14 Sponsor Protocol Number: L00006 CP 403 3A Start Date*: 2008-07-18
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, ...
    Medical condition: The Active substance of Osteopor is Ossein Hydroxyapatite. Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006956 Calcium deficiency LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-006320-20 Sponsor Protocol Number: CT.SVL.PD.10.001 Start Date*: 2012-05-17
    Sponsor Name:Synthon BV
    Full Title: A multicenter, randomized, double-blind, multiple dose, crossover study to evaluate the safety and equivalence of serum phosphate control of a new sevelamer carbonate tablet formulation in compari...
    Medical condition: Evaluation of the safety and equivalence of serum phosphate control of a sevelamer carbonate tablet formulation in comparison with Renvela® in chronic kidney disease patients on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020712 Hyperphosphatemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-016531-35 Sponsor Protocol Number: SPD405-703 Start Date*: 2010-05-18
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo controlled Study to Assess the Effect of Lanthanum Carbonate on intact FGF23 in Normo-phosphataemic Subjects with Sta...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003364-64 Sponsor Protocol Number: SPD405-403 Start Date*: 2007-05-08
    Sponsor Name:Shire Development Inc
    Full Title: A phase IV, open-label, multi-centre trial evaluating the conversion from standard phosphate binder therapy to Fosrenol in chronic kidney disease stage 5 patients on haemodialysis
    Medical condition: Hyperphosphataemia in patients with end-stage renal disease receiving haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IE (Completed) BE (Completed) DK (Prematurely Ended) FR (Completed) AT (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003233-41 Sponsor Protocol Number: SVCARB00105 Start Date*: 2005-10-25
    Sponsor Name:Genzyme Europe BV
    Full Title: An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysis
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    8.0 10009122 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006891-31 Sponsor Protocol Number: RAA/2008/013 Start Date*: 2009-02-17
    Sponsor Name:King's College London
    Full Title: A randomised placebo-controlled trial of Lithium carbonate in Amyotrophic Lateral Sclerosis (LiCALS)
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002026 Amyotrophic lateral sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002329-23 Sponsor Protocol Number: SVCARB07609 Start Date*: 2013-06-20
    Sponsor Name:Genzyme Corporation and its Affiliates
    Full Title: A 2-Week, Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-Month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate ...
    Medical condition: Treatment of hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-008342-20 Sponsor Protocol Number: RAA08-015 Start Date*: 2009-02-23
    Sponsor Name:King's College London
    Full Title: Genetically determined brain abnormalities in Down’s Syndrome.- towards a treatment: A randomised, single-blind, placebo-controlled trial of lithium carbonate in Down’s Syndrome (DownsLit).
    Medical condition: Down's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10013616 Down's syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006413-25 Sponsor Protocol Number: GA0821 Start Date*: 2008-12-09
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A single-centre randomised, partially blind, single dose, crossover study investigating the onset of action of soothing and cooling after taking Gaviscon Peppermint liquid, Double Action Gaviscon ...
    Medical condition: Symptoms of heartburn
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004729-41 Sponsor Protocol Number: ACT 401 Start Date*: 2009-10-27
    Sponsor Name:INEOS Healthcare Limited
    Full Title: An open, randomized, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and lanthanum carbonate together with a randomized placebo controlled double bli...
    Medical condition: Hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000539-42 Sponsor Protocol Number: RB2-NL-1518 Start Date*: 2016-04-15
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A randomised, single dose, crossover, open label, placebo controlled confirmatory study in healthy volunteers to characterise the acid neutralisation activity of Gaviscon Double Action Liquid in th...
    Medical condition: To investigate the pH of the acid in the stomach of healthy volunteers after the intakeof Gaviscon Double Action liquid.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004178-24 Sponsor Protocol Number: RP-OSV-02-D Start Date*: 2013-12-27
    Sponsor Name:Fresenius Medical Care Deutschland GmbH
    Full Title: Study to investigate the therapeutic equivalence of OsvaRen® tablets and OsvaRen® granules
    Medical condition: Hyperphosphataemia in end stage renal failure patients on extracorporeal renal replacement therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004172-30 Sponsor Protocol Number: PREPARE Start Date*: 2021-10-13
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemothe...
    Medical condition: Breast cancer patients scheduled for treatment with paclitaxel chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 01:55:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA